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A morphological evaluation of botulinum neurotoxin A
injections into the detrusor muscle using magnetic resonance
imaging
Abstract
OBJECTIVES: Although botulinum neurotoxin type A (BoNT/A) intradetrusor injections are a
recommended therapy for neurogenic detrusor overactivity (NDO), refractory to antimuscarinic drugs, a
standardisation of injection technique is missing. Furthermore, some basic questions are still
unanswered, as where the toxin solution exactly spreads after injection. Therefore, we investigated the
distribution of the toxin solution after injection into the bladder wall, using magnet resonance imaging
(MRI). METHODS: Six patients with NDO were recruited. Three of six patients received 300 U of
BoNT/A + contrast agent distributed over 30 injection sites (group 1). The other three patients received
300 U of BoNT/A + contrast agent distributed over 10 injection sites (group 2). Immediately after
injection, MRI of the pelvis was performed. The volume of the detrusor and the total volume of contrast
medium inside and outside the bladder wall were calculated. RESULTS: In all patients, a small volume
(mean 17.6%) was found at the lateral aspects of the bladder dome in the extraperitoneal fat tissue,
whereas 82.4% of the injected volume reached the target area (detrusor). In both groups there was a
similar distribution of the contrast medium in the target area. A mean of 33.3 and 25.3% of the total
detrusor volume was covered in group 1 and 2, respectively. Six weeks after injection, five of six
patients were continent and showed no detrusor overactivity in the urodynamic follow-up. No systemic
side effects were observed. CONCLUSIONS: Our results provide morphological arguments that the
currently used injection techniques are appropriate and safe.
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Although botulinum neurotoxin type A (BoNT/A) intradetrusor injections are a 
recommended therapy for neurogenic detrusor overactivity (NDO), refractory to 
antimuscaric drugs, a standardisation of injection technique is missing. Furthermore, 
some basic questions are still unanswered, as where the toxin solution exactly spreads 
after injection. Therefore, we investigated the distribution of the toxin solution after 
injection into the bladder wall, using magnet resonance imaging (MRI). 
 
Methods 
Six patients with NDO were recruited. 3 of 6 patients received 300 units of BoNT/A + 
contrast agent distributed over 30 injection sites (Group 1). The other 3 patients received 
300 units of BoNT-A + contrast agent distributed over 10 injection sites (Group 2). 
Immediately after injection, MRI of the pelvis was performed. The volume of the 
detrusor and the total volume of contrast medium inside and outside the bladder wall 
were calculated.  
 
Results 
In all patients, a small volume (mean 17.6%) was found at the lateral aspects of the 
bladder dome in the extraperitoneal fat tissue, whereas 82.4% of the injected volume 
reached the target area (detrusor). 
In both groups there was a similar distribution of the contrast medium in the target area. 
A mean of 33.3% and 25.3% of the total detrusor volume was covered in group 1 and 2 
2 
respectively. 6 weeks after injection, 5 of 6 patients were continent and showed no DO in 
the urodynamic follow up. No systemic side effects were observed. 
 
Conclusions 
Our results provide morphological arguments that the currently used injection techniques 





















Botulinum neurotoxin type A (BoNT/A) injections into the detrusor muscle is a 
recommended therapy for neurogenic detrusor overactivity (NDO), when antimuscarinic 
drug therapy failed or is not tolerated [1-4]. BoNT/A injections have been successfully 
used to treat NDO worldwide and further indications and therapy options are currently 
explored [5-8]. The toxin is injected into the detrusor muscle via a cystoscopic approach, 
either flexible or rigid. The injection needle, which can be of different length and 
diameter, is stabbed into the bladder wall, followed by the injection of the toxin and the 
retraction of the needle. This is usually performed at multiple sites of the bladder wall, 
depending on the technique and amount of toxin, chosen for therapy [3,9]. Target 
structure of the toxin is the detrusor muscle, as its main mechanism of action is at the 
neuromuscular junction [10,11]. However, detrusor thickness is variable and depends on 
several factors such as gender, age, bladder filling volume and the presence of neurogenic 
lesion or obstruction [12,13]. Although injection is performed under cystoscopic 
guidance, injection depth can only be estimated by the surgeon. Therefore, it remains 
difficult to estimate exactly in which layer the toxin is injected and where it spreads out. 
The sole visual control could be a bulging of the bladder wall after injection. If a big 
transparent bleb forms, the injection was probably superficial in the muscosa, if a slight 
bulging of bladder wall tissue can be observed the injection was probably in the detrusor 
layer. But very often, no bulging can be observed at all and it remains a very insecure 
sign of a correct injection. 
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Although the injection of botulinumtoxin type A is frequently used to treat NDO, no 
standardisation of technique exists [9,14,15]. There are repeatedly reports of treatment 
failures, even in those patients, who formerly showed an excellent treatment response to 
botulinumtoxin [16-18]. Not all treatment failures can be explained properly and one 
reason for this might be a variation in the amount of toxin that reaches its target area. 
Therefore, it was our purpose to investigate for the first time, the distribution of the toxin 
solution after injection into the bladder wall, using magnet resonance imaging (MRI). 
Since we previously investigated the use of two different injection schemes (10 vs. 30 
injection sites), which showed similar clinical results [14], we were also interested to 
observe the morphological outcome of both injection schemes. 
Due to our long term experience with the use of botulinum toxin in the treatment of NDO 
and our favourable results in those years [19,20], we expected most of the toxin to be 
found in the detrusor. Nevertheless we also expected some toxin outside the detrusor, as 
perforation can not be completely excluded using the cystoscopic approach. As a 
secondary outcome measure we evaluated the urodynamical data before and after 
BoNT/A injection to be able to correlate the clinical outcome with the morphological 








Materials and methods 
 
After approval of the local ethics committee, a patient sample was recruited in the 
neurourological out-patient clinic of the spinal cord injury centre at the Balgrist 
University Hospital. 
Inclusion criteria were: urodynamically proven NDO, failure to treatment with 
antimuscarinic drugs, minimum age of 18. 
Exclusion criteria: allergy to botulinum neurotoxin type A or to MRI contrast agents, any 
existing malignancy in the bladder or urethra, urinary tract infection, pregnancy, 
breastfeeding, incapability or unwillingness to perform intermitted selfcatheterisation, 
coagulation disorders or intake of anticoagulant drugs, impaired renal function, 
myasthenia gravis, pacemaker, Lambert-Eaton syndrome, medication with 
aminoglycosides (or other drugs with impact upon neuromuscular transmission), any 
ferromagnetic metal implants or compounds in or at the body. 
Prior to inclusion, all patients were informed about the character of the study, both 
verbally and in writing and each patient had to provide written informed consent. 
Pre-treatment evaluation consisted in physical examination, medical history, 
cystomanometry, blood chemistry, urine sediment and culture. Infections were treated 
according to germ resistance before examination or injection and all patients received 
antibiotic prophylaxis for three days, starting one day before injection and ending one day 
after injection. 
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Local anaesthesia using electromotive drug administration of 2% lidocain was applied in 
patient 2 because of preserved bladder sensibility due to an incomplete spinal cord lesion 
(table 1) [21]. 
The BoNT/A injections were performed at the bladder base and dome in a standardized 
manner by the same surgeon in all patients, using a rigid cystoscope (19 or 22 Fr) and a 
22G (= 0.7mm) needle with a length of 8 mm. Not the full needle length was inserted into 
the bladder wall during injection. Instead, the needle was retracted up to half its length, 
depending on the injection angle. The used BoNT/A compound in this study was 
BOTOX® (Allergan AG, Lachen, Switzerland). 
The first group (Group 1) of patients received 300 units of BOTOX®, distributed over 30 
injection sites à 1ml BoNT/A solution [3]. A second group (Group 2) received 300 units 
of BOTOX®, distributed over 10 injection sites à 1ml BoNT/A solution [14]. For group 1, 
300 units of BOTOX® were diluted in 27 ml 0.9% saline + 3 ml gadopentate. For group 
2, 300 units of BOTOX® were diluted in 9 ml 0.9% saline + 1 ml gadopentate. The 
paramagnetic MRI contrast agent gadopentate (Magnevist®, Schering AG, Berlin, 
Germany) was mixed into the BoNT/A solutions to detect the distribution of the 
injections in the following MR-scans, which were performed in a 1.5 Tesla Avanto 
Siemens Magnetom. Prior to scanning, the bladder of all patients was emptied and filled 
with 200ml 0.9% saline to achieve a standardized filling during MR scanning. 
A T1 fast low angle shot (FLASH) 3D with fat saturation was used in the MR evaluation 
including the following specifications: TR: 4ms, TE: 1,7ms, flipangle: 12 degrees, 
matrix: 256x256, FOV: 200mm, slice thickness: 2,9mm, NEX (Acquisitions): 2. 
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Using the freehand tool of the MR-software, the following regions of interest (ROIs) 
were selected: (1) the area of contrast agent within the detrusor muscle, (2) the area of 
contrast agent outside the detrusor and (3) the whole detrusor itself. Once a ROI was 
defined, the software automatically calculated the area in square millimetres. The 3D 
acquisition technique enabled the generation of volume data by multiplying the 
previously measured ROIs of each slice with the slice thickness. The distribution of 
gadopentate after injection was calculated and evaluated by 2 different radiologists who 
were blinded to the injection protocol. An urodynamic control visit was scheduled for 
each patient three months after injection and the urodynamic outcome measures were 

















6 patients with spinal cord injury and subsequent NDO could be included (table 1). All 
injections could be performed without any clinically evident adverse events and none of 
the patients felt discomfort or pain. Only in patient 6, the injection procedure itself was 
difficult because of an increased spasticity of the lower limb. No systemic side effects 
were observed in any patient directly after the injection or during follow-up. Bleeding 
from the injection sites was minimal and stopped shortly after retracting the needle.  
The average delay between the end of the BoNT/A injection and the start of the first MR-
sequence was 17.5 minutes, ranging from 10 to 32 min. Mean examination time in the 
MRI was 25 minutes, ranging from 17 to 42 minutes. 
In none of the patients, contrast agent could be detected intraperitoneal, which would be 
highly suspicious for a penetration into the peritoneum. Furthermore, no contrast agent 
was found in other organs like the rectum or pelvic muscles. In all six patients, fractions 
of the contrast agent could be detected outside the bladder wall, located in the perivesical 
fat, mainly at the lateral aspects of the bladder dome either on one or both sides. In one 
patient contrast agent was also found beyond the bladder base, in another patient beyond 
the middle part of bladder dome. The average spreading distance of contrast agent from 
the outer margin of the detrusor was 16 mm.  
The mean total detrusor volume of all subjects was 156.4 cm3. The mean contrast 
enhanced detrusor volume of all subjects was 46.3 cm3 (29.3% of the mean total detrusor 
volume). The mean amount of contrast enhanced volume outside the detrusor was 8.7 
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cm3 (17.6% of the mean total contrast enhanced volume). Accordingly, 82.4% of contrast 
agent was found within the detrusor (table 1). 
In group 1, the mean total detrusor volume was 199 cm3. The mean volume of detrusor, 
found to be contrast enhanced, was 62.8 cm3 (33.3% of the mean total detrusor volume in 
group 1). The mean amount of contrast enhanced volume outside the detrusor was 10.7 
cm3 (14.3% of the mean total contrast enhanced volume). Accordingly, 85.7% of contrast 
agent was found within the detrusor (table 1). 
In group 2, the mean total detrusor volume was 113.7 cm3. The mean volume of detrusor, 
found to be contrast enhanced, was 29.9 cm3 (25.3% of the mean total detrusor volume in 
group 2). The mean amount of contrast enhanced volume outside the detrusor was 6.6 
cm3 (20.8% of the mean total contrast enhanced volume). Accordingly, 79.2% of contrast 
agent was found within the detrusor (table 1).  
In five of six patients, the BoNT/A injections showed to be effective. Before treatment, 
all six patients had NDO in their urodynamic examination. The average volume at which 
the first DO could be observed was 234.2 ml. The maximum detrusor pressure was on 
average 44.7 cmH2O. Five of six patients had urinary incontinence (table 1).  
After the BoNT/A injections, four of six patients had no DO up to 500ml and were 
continent. In patient 1 bladder capacity at least increased from 217ml to 381ml and the 
maximum detrusor pressure decreased from 69cmH2O to 57cmH2O (table 1).  Patient 2 
showed no improvement in the follow-up cystometry, although he reported improvement. 
This patient had the lowest percentage of detrusor volume covered by the contrast agent 
(table 1). 
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Due to the spastic limb contractions in patient 6, shifts in the penetration depth of the 
needle might have incidentally occurred. When analyzing this patient’s data we found 
that nearly 40 percent of the applied contrast agent was located beyond the detrusor (table 
1). 






















The aim of this study was to investigate the distribution of the BoNT/A solution, after 
injection into the bladder wall. Our data show, that using the previously described and 
most widely used injection technique with 30 or 10 injection sites [3,14], most of the 
applied volume spreads inside the detrusor. Only small amounts were found outside the 
detrusor, almost exclusively in the fat tissue at the lateral aspects of the bladder dome. 
That 82.4% (average of all 6 subjects) of the injected BoNT/A-gadopentate solution were 
detected inside the detrusor, met our expectations. In regard with the clinical 
improvement of the patients, these results show that the used techniques are accurate and 
efficient. 
Due to the fact, that contrast agent could be detected outside the detrusor, it has to be 
assumed that the injection needle perforated the detrusor during some of the injections. 
This is probably not uncommon following detrusor injections via a cystoscopic approach, 
as the surgeon can only estimate the relation of needle length to detrusor thickness. These 
two factors, e.g. needle length and detrusor thickness, are most crucial in regard to 
injection depth. One can now assume that the surgeon could choose the needle length 
according to the detrusor thickness, which can be measured using ultrasound at a defined 
filling level [12]. This measurement however might not be very reliable during 
cystoscopic BoNT/A injection, as filling volumes and therefore detrusor thickness is 
likely to change during cystoscopy due to diuresis and more likely due to the regular use 
of flushing and draining of saline. Additionally, detrusor thickness might not be the same 
throughout the bladder, although investigated by Kutzmic, who found per individual the 
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same detrusor thickness in all parts of the bladder wall [22]. This is probably true for 
healthy subjects but might be completely different for patients with neurogenic detrusor 
overactivity. 
Perforation might not be the only mechanism contributing to the extravesical amount of 
contrast medium. A diffusion of the BoNT/A-gadopentate solution outside the bladder 
can not be excluded in principle. Although one would expect a more homogeneous and 
broader extravesical accumulation of the contrast medium and not only at certain areas as 
shown in figure 1. 
The amount of the injected BoNT/A-gadopentate solution found outside of the bladder 
wall in the present study seemed to be low enough, not to cause any systemic side effects 
or to compromise the effect of the toxin on the bladder. Most of the intradetrusor contrast 
agent was found in the bladder base and dome, since this are the locations we injected. 
When descriptively comparing the two different treatment modalities (30 vs. 10 injection 
sites) there was a similar amount of contrast agent found in the target area (85.7% vs. 
79.2%) and a similar percentual coverage of detrusor volume with the contrast agent 
(33.3% vs. 25.3%). Although both groups can  not be compared statistically due to the 
small sample size, this finding can still be seen in agreement with the study from 
Karsenty et al. [14], who found no difference in clinical efficacy and safety using 10 
compared to 30 injection sites with the same amount of BoNT/A. 
In general, it remains still unclear, how much detrusor tissue should be covered to gain 
the best dosage/effect ratio of BoNT/A. One would assume that a distribution of BoNT/A 
covering most of the detrusor body might cause the greatest effect. In the present study an 
average of only about 30% (mean of all patients) of detrusor muscle was covered with 
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contrast agent. Nevertheless, a sufficient effect of the BoNT/A treatment could be 
observed, which is well comparable with the success rates reported in former studies 
[6,7]. Therefore, it might not be necessary to cover the whole detrusor with BoNT/A, to 
achieve good clinical results. 
An exact explanation why 30% detrusor coverage with BoNT/A are sufficient enough to 
produce the reported clinically significant improvements can not be given with this study. 
A possible reason eventually underlying these results might be areas of detrusor tissue, 
which are more important for detrusor contraction and increase of local reflex activity 
than other areas after spinal cord injury [23]. Treatment of those areas with BoNT/A 
might be sufficient enough to reduce detrusor contractions in NDO patients, regardless of 
the total amount of detrusor area covered. Experimental studies in neonate and spinal 
cord injured rats showed that spontaneous contractile activity originated in the 
urothelium-suburothelium near the bladder dome [23,24]. This spontaneous activity, 
unlike activity in normal adult rat bladders, is highly organized, i.e. starting at the dome, 
followed by the bladder body further contracting towards the bladder outlet. These 
organized contractions resulted in high amplitudes (10-20 cmH2O). Increased expression 
of gap junctions seems to play a role in this coordinated contraction in neonate and spinal 
cord injury bladders, which gives the impression, that the bladder works partially like a 
“functional syncytium” [24]. 
In addition, BoNT/A is not only inhibiting the efferent pathway by preventing neuronal 
acetylcholine release but also modulating the afferent pathway due to its effect on 
receptors and neurotransmitter release from the urothelium and suburothelium, which 
probably adds to the efficacy of the toxin in the treatment of DO [25-27].  
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Disruption of such organized synergic contractions and of the urothelial and suburothelial 
para- and autocrine signalling by an area of 30% of the total detrusor, due to intradetrusor 
injection of BoNT/A at and around the bladder dome might not completely abolish 
detrusor contractions (Table 1), but prevent complete and/or large amplitude contractions 
arising from the bladder dome. This is probably sufficient enough to prevent incontinence 
and cause satisfying clinical results. Interestingly, two studies mainly using injections at 
the bladder base reported a significant lower rate of complete continent patients with 
NDO compared to other studies injecting BoNT/A in base and dome [7,28,29]. 
Further investigations are necessary to evaluate the degree of detrusor coverage with 
BoNT/A compared with the clinical outcome. Presumably there is an optimal ratio 
between the amount and the degree of distribution of BoNT/A inside the detrusor and the 
clinical outcome, which is worth to be discovered. Using MRI in conjunction with 
contrast enhanced BoNT/A solution, might be a very useful tool to perform this 
investigation.  
There are however limitations of the used investigation method. First limitation is that 
during the injection procedure there might be some volume leaking out of the injection 
site into the bladder lumen. We consider this volume as extremely low, as the needle 
diameter is very small and most injection sites will clot shortly after removing the needle, 
which is in accordance with the experience of Schulte-Baukloh, who investigated toxin 
back flow from the injection site using a dye. He found, although not specifically 
quantified, that none to extremely little dye/toxin is flowing back from the injection sites 
[30]. Quantification of a dye (e.g. methylene blue) in the bladder irrigation fluid requires 
at least a photometric device, which was not readily available in our clinic. The group 
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around Helmut Madersbacher and Gustav Kiss from the University of Innsbruck very 
recently performed such a photometric evaluation and found out that only 1.96-19.2 units 
(median 5.5 units) of 170-400 units BoNT/A are lost due to back flow after injection 
(personal communication, annual meeting of the German Urological Association in 
Stuttgart, 24.-27. Sep 2008).  
Second limitation might be measurement errors. Although most borders could be clearly 
distinguished, extravesical fluid may not have perfectly smooth borders. Manual 
determination of the region of interest introduces an additional small error. These errors 
were minimized by having two senior radiologists experienced in quantitative 
assessments of MR images performing the evaluations in consensus. The remaining error 
is small in comparison to the measured volumes. 
Third limitation is the number of six patients, which is too small to receive data for 
reliable statistics, but besides monetary constraints (expensive MRI-examinations) the 
focus of this study was to demonstrate morphological aspects of the injection technique 
for the first time. The used MRI technique is well suited to demonstrate the morphologic 
situation after injecting the detrusor, but a short delay between injection and obtaining the 
pictures is mandatory because of fast diffusion and venous backflow of the contrast 
agent. 
At least, it has to be considered that we can not demonstrate the localisation of the 
BoNT/A itself, but only the localisation of the contrast agent. Although BoNT/A is not 
residing just at the injection site [31], it propably diffuses much slower and less far as 
gadopentate, due to the higher molecular weight of 150 kD compared to the 835 D of 
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gadopentate. In our study (with a mean delay of 17.5 min after injection) renal excretion 

























Using the previously described injection techniques, a mean of 82.4 % of the injected 
BoNT/A-gadopentate solution can be found within the detrusor. However, a perforation 
of the needle tip and injection into the perivesical tissue could not be prevented. 
Treatment with 10 or 30 injection sites seem similar regarding the distribution of contrast 
agent in or outside the detrusor. In consideration of the clinical improvements of the 
patients, our results provide further arguments that the currently used injection techniques 
are appropriate and safe. Further studies are necessary to explore the optimal ratio 
between the amount and the degree of dissemination of BoNT/A inside the detrusor and 
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Table 1: Patients characteristics, urodynamic data before and after treatment, and the data 
of the magnet resonance imaging analysis of all 6 patients. P = Patient, SCI = spinal cord 
























Fig. 1: An exemplary coronal slice of the magnet resonance imaging of the lower pelvis, 
showing the urinary bladder in the middle of the image.  The contrast agent, appearing in 
white, can be found for the most part within the detrusor (a) and to some extend outside 






 P 1 P 3 P 5 P2 P 4 P 6 
Age 34 34 41 82 67 18 
Sex male male male female male female 
Level of SCI Th11 Th6 Th6 Th7 Th10 Th10 
ASIA classification A A A C A A 
       
Max. bladder capacity before 
treatment [ml] 
217 300 222 217 200 249 
Max. Detrusor pressure before 
treatment [cmH2O] 
69 46 41 37 48 27 
Incontinence/ Urine leak yes yes yes yes yes yes 
       
Units of Botox® 300 300 300 300 300 300 
No. injection sites 30 30 30 10 10 10 
       
Max. bladder capacity after 
treatment [ml] 
381 500 500 186 500 440 
Max. Detrusor pressure after 
treatment [cmH2O] 
57 10 8 36 11 10 
Incontinence/ Urine leak no no no yes no no 
       
Volume detrusor [cm3] 217.16 253.95 126.02 64.55 198.3 78.27 
Volume contrast medium (total) 
[cm3] 
101.53 61.2 57.74 14.51 56.57 38.53 
Volume contrast medium inside 
detrusor [cm3] 
85.6 52.97 49.76 11.52 54.08 24.11 
Volume contrast medium outside 
detrusor [cm3] 
15.93 8.23 7.98 2.99 2.49 14.42 
 

